

Helene Zephir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9110193/publications.pdf>

Version: 2024-02-01

93
papers

5,223
citations

101543
36
h-index

91884
69
g-index

104
all docs

104
docs citations

104
times ranked

5084
citing authors

#	ARTICLE	IF	CITATIONS
1	Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	16
2	A Spontaneous Model of Experimental Autoimmune Encephalomyelitis Provides Evidence of MOG-Specific B Cell Recruitment and Clonal Expansion. <i>Frontiers in Immunology</i> , 2022, 13, 755900.	4.8	8
3	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsingâ€“Remitting Multiple Sclerosis After Fingolimod Withdrawal. <i>Neurotherapeutics</i> , 2022, 19, 476-490.	4.4	5
4	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	7.2	30
5	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€“Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	64
6	Longitudinal Retinal Changes in <scp>MOGAD</scp>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	5.3	20
7	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1556-1563.	3.0	9
8	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. <i>Journal of Neuroradiology</i> , 2021, 48, 28-36.	1.1	24
9	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. <i>Multiple Sclerosis Journal</i> , 2021, 27, 729-741.	3.0	9
10	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.	5.3	123
11	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. <i>Journal of Neuroradiology</i> , 2021, 48, 170-175.	1.1	4
12	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.0	3
13	Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. <i>Brain Communications</i> , 2021, 3, fcab185.	3.3	28
14	The longâ€“term outcome of MOGAD: An observational national cohort study of 61 patients. <i>European Journal of Neurology</i> , 2021, 28, 1659-1664.	3.3	26
15	Comparison of Simoa TM and Ella TM to assess serum neurofilamentâ€“light chain in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1141-1150.	3.7	45
16	Fatal Enterovirus-related Myocarditis in a Patient with Devicâ€™s Syndrome Treated with Rituximab. <i>Cardiac Failure Review</i> , 2021, 7, e09.	3.0	4
17	Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 653577.	4.8	19
18	DMTs and Covidâ€“19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86

#	ARTICLE	IF	CITATIONS
19	The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
20	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Multiple Sclerosis and Related Disorders, 2021, 53, 103076.	2.0	13
21	A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. Annals of Clinical and Translational Neurology, 2021, 8, 2025-2037.	3.7	20
22	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
23	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. JAMA Network Open, 2021, 4, e2128271.	5.9	32
24	Author Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD. Neurology, 2021, 96, 295-296.	1.1	0
25	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Multiple Sclerosis Journal, 2020, 26, 936-944.	3.0	37
26	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. JAMA Neurology, 2020, 77, 94.	9.0	36
27	Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome. Neurology, 2020, 95, e733-e744.	1.1	29
28	Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis. Journal of Clinical Apheresis, 2020, 35, 281-289.	1.3	7
29	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology, 2020, 94, e1645-e1656.	1.1	66
30	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology, 2020, 77, 1079.	9.0	357
31	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. Journal of Neuroinflammation, 2020, 17, 128.	7.2	13
32	Asymptomatic optic nerve lesions. Neurology, 2020, 94, e2468-e2478.	1.1	37
33	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	7.2	115
34	Neurological Involvement in Childhood Evans Syndrome. Journal of Clinical Immunology, 2019, 39, 171-181.	3.8	6
35	Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study. Multiple Sclerosis and Related Disorders, 2019, 33, 39-43.	2.0	4
36	Optical coherence tomography: a window to the optic nerve in clinically isolated syndrome. Brain, 2019, 142, 903-915.	7.6	33

#	ARTICLE	IF	CITATIONS
37	Scl��rose en plaques��: les nouvelles approches physiopathologiques. Pratique Neurologique - FMC, 2019, 10, 112-117.	0.1	0
38	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. Journal of Neurology, 2019, 266, 806-815.	3.6	47
39	Optic nerve double inversion recovery hypersignal in patients with clinically isolated syndrome is associated with asymptomatic gadolinium-enhanced lesion. Multiple Sclerosis Journal, 2019, 25, 1888-1895.	3.0	12
40	Progress in understanding the pathophysiology of multiple sclerosis. Revue Neurologique, 2018, 174, 358-363.	1.5	56
41	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Revue Neurologique, 2018, 174, 255-264.	1.5	47
42	Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmunity Reviews, 2018, 17, 244-255.	5.8	58
43	Proinflammatory B-cell profile in the early phases of MS predicts an active disease. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e431.	6.0	29
44	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869.	1.1	401
45	Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. Journal of Neurology, 2018, 265, 2251-2259.	3.6	29
46	Continuous hemifacial myokymia as the revealing symptom of demyelinating disease of the CNS. Multiple Sclerosis and Related Disorders, 2017, 11, 10-11.	2.0	4
47	Autoimmune cerebellar ataxia with glutamic acid decarboxylase 65 antibodies associated with central vestibular symptoms. Acta Neurologica Belgica, 2017, 117, 775-776.	1.1	1
48	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
49	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?. Multiple Sclerosis and Related Disorders, 2017, 18, 161-163.	2.0	3
50	Late-onset of Alpers-Huttenlocher syndrome: an unusual cause of refractory epilepsy and liver failure. Acta Neurologica Belgica, 2017, 117, 399-401.	1.1	3
51	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1377-1384.	3.0	89
52	Diagnostics diff��rentiels de la scl��rose en plaques. , 2017, , 113-143.		0
53	Signes et sympt��mes de la scl��rose en plaques. , 2017, , 3-78.		0
54	Th��rapeutiques et prise en charge de la scl��rose en plaques. , 2017, , 145-216.		1

#	ARTICLE	IF	CITATIONS
55	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS ONE, 2017, 12, e0168834.	2.5	25
56	Diagnostic positif de la scl�rose en plaques. , 2017, , 79-111.		0
57	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494.	1.1	18
58	Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss. Multiple Sclerosis Journal, 2016, 22, 649-658.	3.0	22
59	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. Multiple Sclerosis and Related Disorders, 2016, 6, 93-96.	2.0	10
60	Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. Brain, 2015, 138, 284-292.	7.6	58
61	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. Journal of Neurology, 2015, 262, 2329-2335.	3.6	86
62	Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. Journal of Neurology, 2015, 262, 1936-1945.	3.6	53
63	A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1781-1793.	3.0	64
64	High-affinity �f1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 2015, 172, 1769-1782.	5.4	15
65	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. PLoS ONE, 2015, 10, e0132033.	2.5	48
66	Switching From Natalizumab to Fingolimod in Multiple Sclerosis. JAMA Neurology, 2014, 71, 436.	9.0	133
67	Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. Multiple Sclerosis Journal, 2014, 20, 1135-1139.	3.0	20
68	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Multiple Sclerosis Journal, 2014, 20, 1086-1094.	3.0	87
69	JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Multiple Sclerosis Journal, 2014, 20, 822-829.	3.0	62
70	Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study. European Radiology, 2014, 24, 3069-3075.	4.5	36
71	Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurology, 2013, 13, 211.	1.8	21
72	Aquaporin-4 antibody�negative neuromyelitis optica. Neurology, 2013, 80, 2194-2200.	1.1	157

#	ARTICLE	IF	CITATIONS
73	Long-term Follow-up of Acute Partial Transverse Myelitis. Archives of Neurology, 2012, 69, 357.	4.5	42
74	Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. Journal of Neurology, 2012, 259, 2293-2298.	3.6	34
75	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Multiple Sclerosis Journal, 2011, 17, 1067-1073.	3.0	144
76	B-cell subsets up-regulate $\alpha 4$ integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset. Neuroscience Letters, 2011, 487, 273-277.	2.1	25
77	Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis. Clinical Immunology, 2011, 139, 12-20.	3.2	19
78	Managing MS in a changing treatment landscape. Journal of Neurology, 2011, 258, 728-739.	3.6	29
79	A Benign Form of Neuromyelitis Optica. Archives of Neurology, 2011, 68, 918.	4.5	54
80	Cognitive function in radiologically isolated syndrome. Multiple Sclerosis Journal, 2010, 16, 919-925.	3.0	116
81	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Multiple Sclerosis Journal, 2010, 16, 87-92.	3.0	43
82	Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob disease. Journal of Neurology, 2009, 256, 134-136.	3.6	8
83	Lumbar punctures: use and diagnostic efficiency in emergency medical departments. International Journal of Emergency Medicine, 2009, 2, 227-235.	1.6	15
84	Optical Coherence Tomography in Clinically Isolated Syndrome. Archives of Neurology, 2009, 66, 1373-7.	4.5	37
85	NMO-IgG and Devic's neuromyelitis optica: a French experience. Multiple Sclerosis Journal, 2008, 14, 440-445.	3.0	107
86	Neuromyelitis Optica and Non-Organ-Specific Autoimmunity. Archives of Neurology, 2008, 65, 78-83.	4.5	497
87	Cognitive Functions in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 84-8.	4.5	98
88	Optical Coherence Tomography in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 920-3.	4.5	96
89	Acute Fulminant Demyelinating Disease. Archives of Neurology, 2007, 64, 1426.	4.5	148
90	Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs. Journal of Neuroimmunology, 2007, 182, 80-88.	2.3	21

#	ARTICLE	IF	CITATIONS
91	Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2006, 179, 53-64.	2.3	25
92	New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunology Letters, 2005, 96, 11-26.	2.5	58
93	Multiple sclerosis and depression: influence of interferon b therapy. Multiple Sclerosis Journal, 2003, 9, 284-288.	3.0	67